投稿一覧に戻る
イミュノメディクス【IMMU】の掲示板
-
>>4
“After conducting a full multi-faceted review of the organizational, operational, and clinical and regulatory capabilities, we are confident that Immunomedics can fully execute on a strategic plan over the next several years to become a recognized leader in the field of antibody-drug conjugates. We now have the financial ability to fully focus on taking the steps to ensure the company has the right leadership, organizational structure and resources necessary to bring IMMU-132 to market and achieve our long-term objectives. The enthusiastic reception from institutional investors to invest in Immunomedics and IMMU-132 reflects the value the company is poised to deliver to patients, employees and stockholders,” Aghazadeh added.
kaz*ヒト投与可能で一斉摘発ｗ
>>3
New strategic plan
Immunomedics also announced additional business and leadership updates and outlined a new strategic plan to drive long-term value for stockholders. The company has raised $125 million in gross proceeds in a private placement of its Series A-1 Convertible Preferred Stock with institutional investors, and has taken a series of steps to drive positive organizational and operational changes.
Focus on IMMU-132
“[These] significant developments [create a] new level of clarity regarding the progress… and the future direction of the company,” noted Behzad Aghazadeh, Chairman of the Board of Immunomedics.